PI3Kalpha inhibitor as well as preparation method and application thereof
Through the structural modification and oxidation reaction of licoriceline compounds, PI3Kα inhibitors with significant target selectivity were prepared, which solved the problem of insufficient selectivity of PI3K inhibitors on PI3Kα subtypes in the prior art, and achieved efficient anti-aging Tumor effect and low toxicity, suitable for clinical applications.
Patent Information
- Application Number
- CN202411035492.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-12-06
AI Technical Summary
The existing PI3K inhibitors have poor selective inhibition of PI3Kα subtype, resulting in serious side effects and cannot meet the clinical demand for targeted selectivity.
Develop a glycyrrhizine compound as a PI3Kα inhibitor. Through structural modification and oxidation reaction, a PI3Kα inhibitor with significant target selectivity is prepared. The specific structure is glycyrrhizine compound and its stereoisomers or pharmaceutically Acceptable salts with effective inhibition of PI3K/Akt/mTOR signaling pathway.
This PI3Kα inhibitor has significant targeted selectivity, significant anti-tumor activity, no obvious toxicity, small dose, cheap synthetic raw materials, low cost, and is suitable for large-scale preparation and production.
Smart Images

Figure CN119080776A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to a PI3Kα inhibitor and a preparation method and application thereof. Background Art
[0002] Tumor is one of the diseases that seriously endangers human health. The global cancer situation is severe, and the incidence and mortality rates are showing a continuous upward trend. At present, the main treatments for cancer are surgical intervention, radiotherapy and chemotherapy. Surgical treatment often needs to be combined with other means to achieve the best treatment effect; the biggest disadvantage of radiotherapy is that it is very harmful to the human body, killing normal cells while killing tumors; chemotherapy may cause potential drug resistance and serious drug side effects.
[0003] Molecular targeted therapy can achieve anti-cancer effects through various mechanisms such as inhibiting cell proliferation, metastasis and angiogenesis, inducing cell apoptosis, and reversing multidrug resistance. In addition, it has strong therapeutic specificity, and targeted drugs are safer and less toxic, and have become an important means of treating cancer.
[0004] PI3K is an intracellular phosphatidylinositol kinase, also known as phosphatidylinositol 3-kinase. It is an important signal transduction molecule in cells and plays an important regulatory role in cell survival, proliferation and differentiation. As a member of the lipid kinase family, it can be divided into three main categories: I, II and III according to its structure and substrate specificity. PI3Kα is an important class I subtype, and abnormal activation promotes cancer cell proliferation, migration, invasion and angiogenesis. Therefore, PI3Kα is regarded as one of the most promising anti-cancer drug targets.
[0005] Currently, a variety of inhibitors with diverse structures have entered the clinical trial stage, but most of them are pan-PI3K inhibitors, such as LY294002, 3-MA, Wortmannin, etc., which usually cause many side effects such as hyperlipidemia, anemia, thrombocytopenia, stomatitis and hepatotoxicity due to their poor inhibition of PI3Kα subtypes. Therefore, it is urgent to develop PI3Kα inhibitors with effective target selectivity to meet the huge clinical needs. Summary of the invention
[0006] In view of this, the object of the present invention is to provide a PI3Kα inhibitor and a preparation method and application thereof. The PI3Kα inhibitor of the present invention has significant targeted PI3Kα inhibitory activity and significant anti-tumor activity.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides a PI3Kα inhibitor, which is a hydrolicycyrrhizin compound, and a stereoisomer or a pharmaceutically acceptable salt thereof. The structural formula of the hydrolicycyrrhizin compound is shown in Formula I or Formula II:
[0009]
[0010] In formula I and formula II, R1 is selected from hydrogen, halogen, methoxy, nitro, cyano, trimethylsilylethynyl or phenyl; R2 is selected from hydrogen or acetonyl; A is selected from hydrogen, tert-butyloxycarbonyl or trichloroethoxycarbonyl;
[0011] In the formula I, R1, R2 and A are not hydrogen at the same time.
[0012] Preferably, the structural formula of the glycyrrhizin compound is Formula I, wherein A is hydrogen, R1 is iodine, bromine, nitro, cyano, trimethylsilylethynyl or phenyl, and R2 is hydrogen.
[0013] Preferably, the structural formula of the glycyrrhizin compound is Formula I, wherein A is tert-butyloxycarbonyl, R1 is hydrogen, iodine or methoxy, and R2 is hydrogen.
[0014] Preferably, the structural formula of the glycyrrhizin compound is Formula I, wherein A is trichloroethoxycarbonyl, R1 is hydrogen, iodine, bromine or nitro; and R2 is hydrogen or acetonyl.
[0015] Preferably, the structural formula of the glycyrrhizin compound is Formula II, A is trichloroethoxycarbonyl, R1 is hydrogen, and R2 is hydrogen.
[0016] Preferably, the glycyrrhizin compound is one of the following structures:
[0017]
[0018]
[0019] The present invention also provides a method for preparing the PI3Kα inhibitor described in the above technical solution, comprising the following steps:
[0020] Using glycyrrhizin as a raw material, structural modification and / or oxidation of the N-4 position are performed to obtain a PI3Kα inhibitor; the positions of the structural modification include at least one of the N-1 position, the C-3 position and the C-10 position; the modification group at the C-10 position is selected from hydrogen, halogen, methoxy, nitro, cyano, trimethylsilylethynyl or phenyl; the modification group at the C-3 position is selected from hydrogen or acetonyl; the modification group at the N-1 position is selected from hydrogen, tert-butyloxycarbonyl or trichloroethoxycarbonyl.
[0021] Preferably, if the structural formula of the hydrolicycitriol compound is Formula I, the modifying group at the N-1 position is trichloroethoxycarbonyl, the modifying group at the C-10 position is hydrogen, and the modifying group at the C-3 position is acetone, the preparation method comprises the following steps:
[0022] After glycyrrhizin is protected by 2,2,2-trichloroethoxycarbonyl, an oxidation reaction is performed, and then a nucleophilic addition reaction is performed to obtain a PI3Kα inhibitor.
[0023] Preferably, if the structural formula of the hydrolicycitriol compound is Formula I, the modifying group at the N-1 position is trichloroethoxycarbonyl, the modifying group at the C-10 position is halogen or nitro, and the modifying group at the C-3 position is acetone, the preparation method comprises the following steps:
[0024] After glycyrrhizin is protected by 2,2,2-trichloroethoxycarbonyl, an oxidation reaction is performed, a nucleophilic addition reaction is performed, and then an aromatic ring substitution reaction or a nitration reaction is performed to obtain a PI3Kα inhibitor.
[0025] The present invention also provides the use of the PI3Kα inhibitor described in the above technical solution or the PI3Kα inhibitor obtained by the above preparation method in the preparation of drugs for preventing and / or inhibiting tumor growth.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The present invention provides a PI3Kα inhibitor, which is a hydrolicycyrrhizin compound, and a stereoisomer or a pharmaceutically acceptable salt thereof. The structural formula of the hydrolicycyrrhizin compound is shown in Formula I or Formula II.
[0028] The PI3Kα inhibitor of the present invention has the characteristics of effectively inhibiting the PI3Kα / Akt / mTOR signaling pathway of PI3Kα, and has significant targeted PI3Kα inhibitory activity; it has significant anti-tumor activity, no obvious toxicity, and a small dosage.
[0029] The present invention also provides a method for preparing the PI3Kα inhibitor described in the above technical solution, which has cheap synthetic raw materials, low cost, simple and green synthetic route, high yield of intermediate products, and is suitable for large-scale preparation and production. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0031] Figure 1 The PI3Kα inhibitory activity results of the compound in Example 13;
[0032] Figure 2 The results of the in vivo antitumor efficacy and toxicity study of the compound of Example 13, wherein (A) is the growth curve of nude mouse body weight; (B) is the curve of mouse tumor volume change; (C) is a representative image of mouse tumor tissue; and (D) is the average tumor weight of mice at the end of the experiment. DETAILED DESCRIPTION
[0033] The present invention provides a PI3Kα inhibitor, which is a hydrolicycyrrhizin compound, and a stereoisomer or a pharmaceutically acceptable salt thereof. The structural formula of the hydrolicycyrrhizin compound is shown in Formula I or Formula II:
[0034]
[0035] In formula I and formula II, R1 is selected from hydrogen, halogen, methoxy, nitro, cyano, trimethylsilylethynyl or phenyl; R2 is selected from hydrogen or acetonyl; A is selected from hydrogen, tert-butyloxycarbonyl or trichloroethoxycarbonyl;
[0036] In the formula I, R1, R2 and A are not hydrogen at the same time.
[0037] In the present invention, the halogen preferably includes iodine or bromine, the structural formula of the tert-butyloxycarbonyl (-Boc) group is shown in Formula III, and the structural formula of the trichloroethoxycarbonyl (-Troc) group is shown in Formula IV:
[0038]
[0039] In the present invention, the structural formula of the hydrolicycyrrhizin compound is preferably Formula I, wherein A is hydrogen, R1 is iodine, bromine, nitro, cyano, trimethylsilylethynyl or phenyl, and R2 is hydrogen;
[0040] The structural formula of the hydrolicycitriol compound is preferably Formula I, wherein A is tert-butyloxycarbonyl, R1 is hydrogen, iodine or methoxy, and R2 is hydrogen;
[0041] The structural formula of the hydrolicycithin compound is preferably Formula I, wherein A is trichloroethoxycarbonyl, R1 is hydrogen, iodine, bromine or nitro, and R2 is hydrogen or acetonyl;
[0042] The structural formula of the glycyrrhizin compound is preferably Formula II, and A is preferably trichloroethoxycarbonyl, R1 is hydrogen, and R2 is hydrogen.
[0043] In the present invention, the arrow between nitrogen and oxygen in Formula II represents a coordination bond.
[0044] In the present invention, the glycyrrhizin compound is preferably one of the following structures:
[0045]
[0046] In the present invention, the pharmaceutically acceptable salt preferably includes an organic acid salt or an inorganic acid salt, and the organic acid salt preferably includes tartrate, citrate, formate, acetate, lactate, pyruvate, ferulate, fumarate, succinate, salicylate or oxalate; the inorganic acid salt preferably includes hydrochloride, hydrobromide, nitrate, phosphate, carbonate or sulfate.
[0047] In the present invention, the PI3Kα inhibitor is preferably derived from chemical synthesis or natural products.
[0048] The present invention also provides a method for preparing the PI3Kα inhibitor described in the above technical solution, comprising the following steps:
[0049] Using glycyrrhizin as a raw material, structural modification and / or oxidation of the N-4 position are performed to obtain a PI3Kα inhibitor; the positions of the structural modification include at least one of the N-1 position, the C-3 position and the C-10 position; the modification group at the C-10 position is selected from hydrogen, halogen, methoxy, nitro, cyano, trimethylsilylethynyl or phenyl; the modification group at the C-3 position is selected from hydrogen or acetonyl; the modification group at the N-1 position is selected from hydrogen, tert-butyloxycarbonyl or trichloroethoxycarbonyl.
[0050] In the present invention, unless otherwise specified, the materials and equipment used are commercially available products in the art.
[0051] In the present invention, the structural formula of the tabersonine is as shown in Formula V:
[0052]
[0053] In the present invention, the carbon to which R1 in Formula I and Formula II is connected is the C-10 position, the carbon to which R2 is connected is the C-3 position; and the nitrogen to which A is connected is the N-1 position.
[0054] In the present invention, the structural modification preferably includes one or more of aromatic ring halogenation, nitration reaction, electrophilic substitution reaction, tert-butyloxycarbonylamino protection, Suzuki-Miyaura coupling reaction-reduction, 2,2,2-trichloroethoxycarbonyl protection and nucleophilic addition reaction.
[0055] 1) If the structural formula of the hydrolicycyrrhizin compound is preferably Formula I, the modifying group at the N-1 position is hydrogen, and the modifying group at the C-3 position is hydrogen:
[0056] When the modification group at the C-10 position is iodine, bromine or nitro, the preparation method of the PI3Kα inhibitor comprises the following steps (see reaction formula in route 1):
[0057] The aromatic ring of glycyrrhizin is subjected to halogenation or nitration reaction to obtain a PI3Kα inhibitor (2a to 2c in route 1).
[0058] In the present invention, the raw materials for the aromatic ring halogenation reaction preferably also include N-iodosuccinimide or N-bromosuccinimide, and the reaction solvent is preferably trifluoroacetic acid; the molar ratio of N-iodosuccinimide or N-bromosuccinimide to glycyrrhizin is preferably (1.1-1.5):1, the temperature of the aromatic ring halogenation reaction is preferably room temperature, and the time is preferably 8 hours.
[0059] In the present invention, the aromatic ring halogenation reaction preferably further includes a first post-treatment, and the first post-treatment preferably includes: adjusting the pH value of the reaction system to 7-8, extraction, washing, drying with a desiccant and separation by silica gel column chromatography; the adjusting agent for adjusting the pH value of the reaction system is preferably a saturated sodium bicarbonate solution; the washing reagent is preferably a saturated sodium chloride solution; the desiccant is preferably anhydrous sodium sulfate; the eluent for the silica gel column chromatography separation is preferably a mixture of petroleum ether and acetone in a volume ratio of 60:1.
[0060] In the present invention, the raw material system of the nitration reaction preferably also includes: dichloromethane, trifluoroacetic acid, trifluoroacetic anhydride and ammonium nitrate; the molar ratio of the ammonium nitrate to glycyrrhizin is preferably (1.0-1.2):1; the temperature of the nitration reaction is preferably 0°C, and the time is preferably 30 minutes.
[0061] In the present invention, the nitration reaction preferably further includes a second post-treatment, and the second post-treatment is preferably consistent with the first post-treatment, except that the eluent for silica gel column chromatography separation is replaced with a mixture of petroleum ether and acetone in a volume ratio of 20:1.
[0062] When the modification group at the C-10 position is cyano, phenyl or trimethylsilylethynyl, the method for preparing the PI3Kα inhibitor preferably comprises the following steps (see reaction formula in Scheme 1):
[0063] The hydrolicycithin is subjected to an aromatic ring halogenation reaction and then an electrophilic substitution reaction to obtain a PI3Kα inhibitor (3a to 3c in route 1).
[0064] In the present invention, the electrophilic substitution reaction adopts the conditions and methods commonly used in the art to obtain a cyano group, a phenyl group or a trimethylsilylethynyl group at the C-10 position.
[0065] 2) If the structural formula of the hydrolicycyrrhizin compound is preferably Formula I, the modifying group at the N-1 position is tert-butyloxycarbonyl, the modifying group at the C-10 position is hydrogen, and the modifying group at the C-3 position is hydrogen:
[0066] The method for preparing the PI3Kα inhibitor preferably comprises the following steps (see reaction formula in route 1):
[0067] Glycyrrhizin, di-tert-butyl dicarbonate, 4-dimethylaminopyridine and tetrahydrofuran are mixed to perform the first tert-butyloxycarbonylamino protection to obtain a PI3Kα inhibitor (2d in route 1).
[0068] In the present invention, the molar ratio of glycyrrhizine, di-tert-butyl dicarbonate and 4-dimethylaminopyridine is preferably 1:2:0.1.
[0069] In the present invention, the first tert-butyloxycarbonylamino protection preferably further includes a third post-treatment, and the third post-treatment preferably includes: concentration under reduced pressure, adding dichloromethane, washing, drying with a desiccant, and separation by silica gel column chromatography.
[0070] The reaction equation of route 1 is as follows:
[0071]
[0072] 3) If the structural formula of the hydrolicycyrrhizin compound is preferably Formula I, the modifying group at the N-1 position is tert-butyloxycarbonyl, and the modifying group at the C-3 position is hydrogen:
[0073] When the modification group at the C-10 position is preferably iodine, the method for preparing the PI3Kα inhibitor preferably comprises the following steps (see reaction formula in route 2): subjecting glycyrrhizin to aromatic ring halogenation reaction, followed by second tert-butyloxycarbonylamino protection to obtain the PI3Kα inhibitor (4 in route 2).
[0074] In the present invention, the second tert-butoxycarbonylamino protection is preferably consistent with the first tert-butoxycarbonylamino protection conditions, which will not be repeated here.
[0075] When the modification group at the C-10 position is preferably a methoxy group, the preparation method of the PI3Kα inhibitor preferably includes the following steps (see the reaction formula in Scheme 2): subjecting glycyrrhizin to an aromatic ring halogenation reaction, performing a second tert-butyloxycarbonylamino protection, and then performing a Suzuki-Miyaura coupling reaction-reduction to obtain a PI3Kα inhibitor (5 in Scheme 2).
[0076] The reaction formula of route 2 is as follows:
[0077]
[0078] 4) If the structural formula of the hydrolicycyrrhizin compound is preferably Formula I, the modifying group at the N-1 position is trichloroethoxycarbonyl, and the modifying group at the C-3 position is hydrogen:
[0079] When the modification group at the C-10 position is preferably hydrogen, the method for preparing the PI3Kα inhibitor preferably comprises the following steps (see reaction formula in Scheme 3):
[0080] The 2,2,2-trichloroethoxycarbonyl group of glycyrrhizine was protected to obtain a PI3Kα inhibitor (6 in route 3).
[0081] When the modification group at the C-10 position is preferably a nitro group, the preparation method of the PI3Kα inhibitor comprises the following steps (see reaction formula in Scheme 3):
[0082] After glycyrrhizin is protected by 2,2,2-trichloroethoxycarbonyl, an electrophilic substitution reaction is performed to obtain a PI3Kα inhibitor (7 in route 3).
[0083] 5) If the structural formula of the hydrolicycyrrhizin compound is preferably Formula II, the modifying group at the N-1 position is preferably trichloroethoxycarbonyl, the modifying group at the C-10 position is preferably hydrogen, and the modifying group at the C-3 position is preferably hydrogen:
[0084] The method for preparing the PI3Kα inhibitor preferably comprises the following steps (see reaction formula in route 3):
[0085] After glycyrrhizine is protected by 2,2,2-trichloroethoxycarbonyl, an oxidation reaction is performed to obtain a PI3Kα inhibitor (8 in route 3).
[0086] 6) If the structural formula of the hydrolicycyrrhizin compound is preferably Formula I, the modifying group at the N-1 position is preferably trichloroethoxycarbonyl, the modifying group at the C-10 position is preferably hydrogen, and the modifying group at the C-3 position is preferably acetonyl:
[0087] The method for preparing the PI3Kα inhibitor preferably comprises the following steps (see reaction formula in route 3):
[0088] After 2,2,2-trichloroethoxycarbonyl protection is performed on glycyrrhizin, an oxidation reaction is performed, and then a nucleophilic addition reaction is performed to obtain a PI3Kα inhibitor (9 in route three).
[0089] In the present invention, the nitrogen-oxygen coordination bond undergoes a Polonovoski reaction to form an imine.
[0090] 7) If the structural formula of the hydrolicycitriol compound is preferably Formula I, the modifying group at the N-1 position is preferably trichloroethoxycarbonyl, the modifying group at the C-10 position is preferably halogen or nitro, and the modifying group at the C-3 position is preferably acetonyl:
[0091] The method for preparing the PI3Kα inhibitor preferably comprises the following steps (see reaction formula in route 3):
[0092] After 2,2,2-trichloroethoxycarbonyl protection is performed on glycyrrhizin, an oxidation reaction is performed, followed by a nucleophilic addition reaction, and then an aromatic ring substitution reaction or a nitration reaction is performed to obtain a PI3Kα inhibitor (10a to 10c in route three).
[0093] The reaction formula of route 3 is as follows:
[0094]
[0095] The present invention also provides the use of the PI3Kα inhibitor described in the above technical solution in the preparation of a drug for preventing and / or inhibiting tumor growth.
[0096] In the present invention, the tumor preferably includes: lung cancer, breast cancer, human oral epidermoid carcinoma, nasopharyngeal carcinoma, colon cancer, bladder cancer, liver cancer, stomach cancer, pancreatic cancer, cervical cancer or head and neck cancer.
[0097] The PI3Kα inhibitor of the present invention can reverse tumor drug resistance and treat excessive proliferation, cell growth inhibition or cytotoxicity of tumor cells.
[0098] To further illustrate the present invention, the PI3Kα inhibitor provided by the present invention and its preparation method and application are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0099] In the specific examples, the experimental reagents involved were purchased from suppliers, such as Shanghai Titan Technology Co., Ltd., Aladdin Reagent Co., Ltd., etc. All reagents were used directly without further purification unless otherwise specified. Common reagents were purchased from Yunnan Liyan Technology Co., Ltd. and Qingdao Ocean Chemical Co., Ltd.
[0100] The instruments used, such as NMR spectrum, were tested by Bruker AV-500MHz or Bruker Avance III 600MHz, with TMS as the internal standard; ESI was measured by Aglient 1290UPLC / 6540Q-TOFQ LC / MS system. The chromatographic columns used in the examples were silica gel of 80-100 mesh and 200-300 mesh and silica gel H (40 μm), purchased from Qingdao Ocean Chemical Co., Ltd., China.
[0101] In the specific examples, in order to briefly explain the experimental process, some professional terms and chemical reagents involved are described by abbreviations, and these abbreviations are compared with their full names as follows: When characterizing NMR data, s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants are expressed in Hertz (Hz). DCM is CH2Cl2, i.e. dichloromethane; CDC13 is deuterated chloroform; TEA and Et3N are triethylamine; THF is tetrahydrofuran; DMAP is 4-dimethylaminopyridine; DMF is N,N-dimethylformamide; NaOH is sodium hydroxide; TFAA is trifluoroacetic anhydride; TFA is trifluoroacetic acid; m-CPBA is m-chloroperbenzoic acid; NIS is N-iodosuccinimide; NBS is N-bromosuccinimide; NaCl is sodium chloride.
[0102] Example 1
[0103] (3aR,10bR,13S,3a 1 S)-3a-ethyl-9-iodo-3a,3a 1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (Compound 2a) has the following structural formula and synthesis steps:
[0104]
[0105] Dissolve tabersonine (3.4 g, 10.1 mmol) in 10 mL TFA (trifluoroacetic acid), slowly add N-iodosuccinimide NIS (246.4 mg), and react at room temperature for 8 hours. After the reaction is completed by TLC monitoring, remove TFA by vacuum concentration, and then slowly add saturated sodium bicarbonate solution to the system at 0°C to adjust the pH to 7-8. Extract with ethyl acetate 3 times, then wash with NaClsat.aq. (saturated brine) (40 mL×2), and finally dry with anhydrous sodium sulfate, combine the organic phases and concentrate under reduced pressure, separate by silica gel column chromatography (petroleum ether: acetone volume ratio = 60:1), and obtain the target product 2a (3.3 g, yield 70%).
[0106] NMR data: 13 C NMR (125MHz, CDCl3)δ C168.9(s),165.5(s),143.0(s),140.7(s),136.4(d),132.9(d),130.4(d),124.9(d),111.3(d),92.9(s) ,82.4(s),70.1(d),55.1(s),51.1(q),51.0(t),50.4(t),44.5(t),41.1(s),28.5(t),27.0(t),7.5(q).
[0107] Example 2
[0108] (3aR,10bR,13S,3a 1 S)-9-bromo-3a-ethyl-3a,3a 1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (compound 2b) has the following structural formula and synthesis steps:
[0109]
[0110] Dissolve tabersonine (34 mg, 0.1 mmol) in 2 mL TFA, slowly add N-bromosuccinimide NBS (19.6 mg), and react at room temperature for 8 hours. After the reaction is completed by TLC monitoring, concentrate under reduced pressure to remove TFA, and then slowly add saturated sodium bicarbonate solution to the system at 0°C to adjust the pH to 7-8. Extract with ethyl acetate 3 times, then wash with NaClsat.aq. (40 mL×2), and finally dry with anhydrous sodium sulfate, combine the organic phases and concentrate under reduced pressure, separate by silica gel column chromatography (petroleum ether: acetone volume ratio = 60:1), and obtain the target product 2b (33 mg, yield 70%).
[0111] NMR data: 13 C NMR (125MHz, CDCl3)δ C 168.9(s),165.8(s),142.3(s),140.2(s),132.8(d),130.4(d),124.9(d),124.8(d),112.8(s),110.7(d) ),92.9(s),70.1(d),55.2(s),51.2(q),50.9(t),50.4(t),44.5(t),41.1(s),28.4(t),26.9(t),7.5(q).
[0112] Example 3
[0113] (3aR,10bR,13S,3a 1 S)-3a-ethyl-9-nitro-3a,3a1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (Compound 2c) has the following structural formula and synthesis steps:
[0114]
[0115] Tabersonine (68 mg, 0.2 mmol) was dissolved in 5 mL DCM (dichloromethane), TFA (2.0 eq) was added at 0°C, and then TFAA trifluoroacetic anhydride (2.0 eq) and NH4NO3 (1.0 eq) were added respectively, and the reaction was carried out at 0°C for 30 min. The reaction was monitored by TLC, and the pH was adjusted to 7-8 with saturated sodium bicarbonate solution, extracted with ethyl acetate 3 times, and the organic phase was washed with saturated sodium chloride (40 mL×2), and finally dried over anhydrous sodium sulfate. After concentration under reduced pressure, the product was separated by silica gel column chromatography (petroleum ether: acetone = 20:1) to obtain the target product 2c (22.0 mg, yield 68%).
[0116] NMR data: 13 C NMR (125MHz, CDCl3)δ C 166.2(s),148.3(s),147.3(s),132.2(d),126.2(d),124.6(d),122.9(d),116.9(d),93.1(s) ,71.8(d),62.1(s),54.4(q),53.8(t),51.7(t),41.1(t),40.3(s),36.0(t),27.5(t),8.2(q).
[0117] Example 4
[0118] (3aR,10bR,13S,3a 1 S)-3a-ethyl-6-{[(2-methylpropan-2-yl)oxy]carbonyl}-3a,3a 1 The structural formula and synthesis steps of methyl 4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate (compound 2d) are as follows:
[0119]
[0120] Dissolve tabersonine in 3 mL of THF, add a catalytic amount of 4-dimethylaminopyridine DMAP (0.1 eq), then add di-tert-butyl dicarbonate Boc2O (3.0 eq), and react at 60°C for 4 hours. After TLC monitoring, the reaction was completed, concentrated under reduced pressure, added with dichloromethane (50 mL), washed with water (20 mL×3), and dried over anhydrous sodium sulfate. Separated by silica gel column chromatography (petroleum ether: acetone = 60:1), the target product 2d was obtained (yield 14%).
[0121] NMR data: 13 C NMR (125MHz, CDCl3)δ C 168.4(s),151.4(s),150.3(s),140.9(s),138.7(s),133.0(d),127.7(d),125.4(d),123.7(d),121.2(d),116.3(d),111.9(s),8 2.5(s),68.2(d),53.7(t),52.8(s),51.8(q),51.7(t),51.2(t),43.3(t),41.8(s),31.6(t),31.5(t),28.5(q),26.7(t),7.9(q).
[0122] Example 5
[0123] (3aR,10bR,13S,3a 1 S)-9-cyano-3a-ethyl-3a,3a 1 The structural formula and synthesis steps of methyl 4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate (compound 3a) are as follows:
[0124]
[0125] Compound 2a (46.2 mg, 0.1 mmol), potassium ferrocyanide trihydrate (0.04 mmol), and Pd(PPh3)4 (content of triphenylphosphine palladium 5 mol%) in Example 1 were placed in a two-necked flask, the system was replaced with nitrogen several times, and t-BuOH / H2O (volume ratio 1:1) was added, and the reaction was carried out at room temperature for 10 minutes, and then the temperature was raised to 80°C for 8 hours. After the reaction was completed by TLC monitoring, methanol was added for dilution, the sample was filtered through diatomaceous earth, concentrated under reduced pressure, and separated by column chromatography (petroleum ether: acetone = 25:1) to obtain the target product 3a (27.6 mg, yield 75%).
[0126] NMR data: 13 C NMR (125MHz, CDCl3)δ C168.7(s),164.2(s),147.0(s),138.9(s),133.3(d),132.5(d),125.1(d),125.0(s),119.9(s),109.5(d),103.1(s),95 .2(s),69.9(d),54.6(s),51.3(q),51.0(t),50.3(t),44.6(t),41.0(s),30.9(q),28.7(t),27.9(q),27.1(t),7.5(q).
[0127] Example 6
[0128] The structural formula and synthesis steps of (3aR,10bR,13S,3a1S)-3a-ethyl-9-phenyl-3a,3a1,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (compound 3b) are as follows:
[0129]
[0130] Compound 2a (46.2 mg, 0.1 mmol) in Example 1, phenylboric acid (0.2 mmol), potassium carbonate (K2CO3, 0.16 mmol), and Pd(PPh3)4 (5 mol%) were placed in a two-necked bottle, replaced with nitrogen three times, and dry toluene was added; heated to 100°C for 12 hours. After the reaction was completed by TLC monitoring, toluene was dried and separated by silica gel column chromatography (petroleum ether: acetone = 40: 1) to obtain the target product 3b (32 mg, yield 78%).
[0131] NMR data: 13 C NMR (125MHz, CDCl3)δ C 169.0(s),166.5(s),142.7(s),141.4(s),138.8(s),134.1(d),133.0(d),128.8(d),126.8(d),126.7(d),126.7(d),124.9(d),12 0.4(d),109.4(d),92.5(s),70.2(d),55.2(s),51.1(q),51.0(t),50.6(t),44.6(t),41.3(s),31.3(q),28.5(t),27.0(t),7.5(q).
[0132] Example 7
[0133] (3aR,10bR,13S,3a 1The structural formula and synthesis steps of methyl 3a-ethyl-9-[(trimethylsilyl)ethynyl]-3a,3a1,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate (compound 3c) are as follows:
[0134]
[0135] Compound 2a (23.1 mg, 0.05 mmol) in Example 1, trimethylsilyl acetylene (0.2 mmol), Pd(PPh3)4 (5 mol%) and CuI (5 mol%) were added to a two-necked bottle, and DMF / Et3N (1:1, 2 mL) was added. The system was quickly replaced with nitrogen three times. The reaction temperature was raised to 100°C for 12 hours. After the reaction was completed by TLC monitoring, ethyl acetate was added to dilute the reaction solution, the reaction solution was filtered through diatomaceous earth, water was added, and ethyl acetate was extracted three times. The organic phase was washed with NaCl sat.aq. (40 mL×2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by silica gel column chromatography (petroleum ether: acetone = 50:1) to obtain the target product 3c (15 mg, yield 69%).
[0136] NMR data: 13 C NMR (125MHz, CDCl3)δ C 168.8(s),165.7(s),143.4(s),138.0(s),132.8(d),132.4(d),125.0(d),124.8(d),114.6(s),109.0(d),105.8(s) ),93.2(s),92.2(s),69.8(d),54.7(s),51.0(q),50.8(t),50.4(t),44.4(t),41.2(s),28.4(t),26.8(t),7.4(q).
[0137] Example 8
[0138] (3aR,10bR,13S,3a 1 S)-3a-ethyl-9-iodo-6-{[(2-methylpropan-2-yl)oxy]carbonyl}-3a,3a 1 , the synthesis steps of 4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (Compound 4) are as follows:
[0139]
[0140] Compound 2a (23.0 mg, 0.05 mmol) in Example 1 was dissolved in 3 mL of THF, and a catalytic amount of DMAP (0.1 eq) was added, followed by Boc2O (3.0 eq), and the mixture was reacted at 60°C for 4 hours. The reaction was monitored by TLC, and the mixture was concentrated under reduced pressure, and dichloromethane (50 mL) was added, washed with water (20 mL×3), and dried over anhydrous sodium sulfate. The target product 4 (23.8 mg, yield 85%) was obtained by silica gel column chromatography (petroleum ether: acetone = 60:1).
[0141] NMR data: 13 C NMR (125MHz, CDCl3)δ C 167.9(s),150.7(s),149.1(s),141.0(s),140.5(s),136.4(d),132.4(d),129.8(d),125.1(d),118.0(d),111.9(s),86.6(s),82 .6(s),68.1(d),52.5(s),51.6(q),51.3(t),50.8(t),43.0(t),41.3(s),31.1(t),28.1(q),27.9(q),26.4(t),25.6(t),7.6(q).
[0142] Example 9
[0143] (3aR,10bR,13S,3a 1 S)-3a-ethyl-9-iodo-6-{[(2-methylpropan-2-yl)oxy]carbonyl}-3a,3a 1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (Compound 5) has the following structural formula and synthesis steps:
[0144]
[0145] Step 1: Dissolve compound 4 (28.0 mg, 0.05 mmol) in Example 8 in THF and stir at room temperature. Then add Cs2CO3 (0.075 mmol), B2Pin2 (0.075 mmol), CuI (0.2 mmol), PPh3 (0.2 mmol) and Pd(OAc)2 (0.2 mmol) to the reaction system and react for 24 hours. After the reaction is completed, filter with diatomaceous earth to obtain intermediate A (3aR, 10bR, 13S, 3a 1 S)-3a-ethyl-6-{[(2-methylpropan-2-yl)oxy]carbonyl}-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3a,3a1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester.
[0146] Step 2: Take the dried intermediate A (3aR, 10bR, 13S, 3a 1 S)-3a-ethyl-6-{[(2-methylpropan-2-yl)oxy]carbonyl}-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3a,3a 1 ,4,6,11,12-hexahydro-1H-indolizine [8,1-cd] carbazole-5-carboxylic acid methyl ester was dissolved in THF, 2M NaOH (7eq) and H2O2 (2eq) were added, stirred at room temperature, and reacted for 2 hours. After the reaction, it was extracted with saturated sodium sulfite solution and ethyl acetate, repeated 3 times, and the organic phase was washed with NaCl sat.aq. (40mL×2), and then dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by silica gel column chromatography (petroleum ether: acetone = 5:1) to obtain intermediate B (3aR, 10bR, 13S, 3a 1 S)-3a-ethyl-9-hydroxy-6-{[(2-methylpropan-2-yl)oxy]carbonyl}-3a,3a1,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (18.0 mg, yield 70%).
[0147] Intermediate B NMR data: 13 C NMR (125MHz, CDCl3)δ C 168.2(s),152.1(s),151.2(s),150.0(s),140.1(s),134.1(s),132.7(d),125.1(d),116.9(d),113.4(d),111.7(s),108 .9(d),82.1(s),68.1(d),52.6(s),51.6(q),51.4(t),51.0(t),42.9(t),41.4(s),31.2(t),3×28.2(q),26.4(t),7.6(q).
[0148] Step 3: Intermediate B (3aR, 10bR, 13S, 3a 1S)-3a-ethyl-9-hydroxy-6-{[(2-methylpropan-2-yl)oxy]carbonyl}-3a,3a1,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (46.2 mg, 0.1 mmol) and 4-methoxyphenylboronic acid (0.2 mmol), potassium carbonate (K2CO3, 0.16 mmol), Pd(PPh3)4 (5 mol%) were added to a two-necked flask in sequence, replaced with nitrogen three times, and dry toluene was added; heated to 100°C for 12 hours. After the reaction was completed by TLC monitoring, the toluene was dried and separated by silica gel column chromatography (petroleum ether: acetone = 40:1) to obtain the target product 5 (36.7 mg, yield 83%).
[0149] NMR data: 13 C NMR (125MHz, CDCl3)δ C C169.0(s),166.8(s),158.7(s),142.2(s),139.0(s),133.9(s),133.8 (d),133.1(s),127.8(d),127.8(d),126.3(d),124.9(d),120.1(d),11 4.2(d),114.4(d),109.4(d),92.3(s),70.2(d),55.4(q),55.4(s),51. 1(t),51.1(t),50.6(q),44.6(t),41.3(s),28.5(t),27.0(t),7.5(q).
[0150] Example 10
[0151] (3aR,10bR,13S,3a 1 S)-3a-ethyl-6-{[(2,2,2-trichloroethyl)oxy]carbonyl}-3a,3a 1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (Compound 6) has the following structural formula and synthesis steps:
[0152]
[0153] Tabersonine (3.4 g, 10.1 mmol) was dissolved in a mixed solution of THF and DMF (volume ratio 3:1), placed in a three-necked flask for reaction, and DMAP (2.0 eq), NaH (5.0 eq), and then Troc-Cl (3.0 eq) were added in sequence at 0°C, and the reaction was maintained at 0°C for 8 hours. The reaction was monitored by TLC, quenched with water, and the pH was adjusted to 7-8 with a saturated sodium bicarbonate solution. Ethyl acetate was added for extraction 3 times, and then washed with NaCl sat.aq. (40 mL×2), and finally dried with anhydrous sodium sulfate, the organic phases were combined and concentrated under reduced pressure, and separated by silica gel column chromatography (petroleum ether: acetone = 70:1) to obtain the target product 6 (4.7 g, yield 92%).
[0154] NMR data: 13 C NMR (125MHz, CDCl3)δ C 167.1(s),150.7(s),142.5(s),139.7(s),138.2(s),132.6(d),127.8(d),125.2(d),124.5(d),121.2(d),116.1(d) ),112.6(s),94.7(s),75.7(t),51.7(q),51.5(t),51.0(t),42.7(t),41.5(s),31.0(q),30.9(t),26.4(t),7.6(q).
[0155] Embodiment 11
[0156] The structural formula and synthesis steps of [(3aR,10bR,13S,3a1S)-3a-ethyl-9-nitro-6-{[(2,2,2-trichloroethyl)oxy]carbonyl}-3a,3a1,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester] (Compound 7) are as follows:
[0157]
[0158] Compound 6 (51.0 mg, 0.1 mmol) in Example 10 was dissolved in dichloromethane (DCM, 5 mL), TFA (2 mL), TFAA (0.2 mmol) were added at 0°C, followed by ammonium nitrate (NH4NO3, 0.1 mmol), and the reaction was continued for 30 minutes. The reaction was monitored by TLC, and the pH was adjusted to 7-8 with a saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate 3 times, and the organic phase was washed with NaCl sat.aq. (40 mL×2), and finally dried with anhydrous sodium sulfate. The mixture was spin-dried and separated by silica gel column chromatography (petroleum ether: acetone = 20:1) to obtain the target product compound 7 (45.5 mg, yield 82%).
[0159] NMR data: 13 C NMR (125MHz, CDCl3)δ C 166.6(s),150.2(s),149.7(s),145.0(s),144.4(s),139.8(s),131.9(d),125.4(d),124.8(d),116.9(d),115.6(d),11 3.6(s),94.4(s),76.0(t),67.9(d),52.6(s),51.9(q),51.4(t),50.9(t),42.8(t),41.4(s),30.7(t),26.4(t),7.6(q).
[0160] Example 12
[0161] (3aR,10bR,3a 1 S)-3a-ethyl-13-oxo-6-{[(2,2,2-trichloroethyl)oxy]carbonyl}-3a,3a 1 ,4,6,11,12-hexahydro-1H-13λ 4 The structural formula and synthesis steps of methyl indolizino[8,1-cd]carbazole-5-carboxylate (Compound 8) are as follows:
[0162]
[0163] Compound 6 (510 mg, 1 mmol) in Example 10 was dissolved in DCM, cooled to 0°C, and m-CPBA (2.2 mmol) was added. After reacting for 10 minutes (the reaction was monitored by TLC), 10% sodium carbonate was added for extraction. The extraction was repeated 4 times, and the organic phases were combined and washed with NaClsat.aq. (40 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the target product 8 (489 mg, yield 93%).
[0164] NMR data: 13 C NMR (125MHz, CDCl3)δ C 166.8(s),150.8(s),150.1(s),139.8(s),136.7(s),131.4(d),128.7(d),127.1(d),125.7(d),118.1(d),115.4(d) ),109.8(s),94.4(s),82.8(d),76.0(t),68.2(t),63.0(t),54.8(s),52.0(q),41.3,(t)34.9(t),31.4(t),7.9(q).
[0165] Embodiment 13
[0166] (1R,3aR,10bR,13S,3a 1 S)-3a-ethyl-1-(2-oxypropylidene)-6-{[(2,2,2-trichloroethyl)oxy]carbonyl}-3a,3a 1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester (Compound 9) has the following structural formula and synthesis steps:
[0167]
[0168] Compound 8 in Example 12 was dissolved in dry DCM, trifluoroacetic anhydride (TFAA, 2 mmol) was added at 0°C, the reaction was carried out for 1 hour at 0°C, and then for 1.5 hours at room temperature. After the reaction was completed by TLC monitoring, the solvent was dried (using an oil pump to drain the solvent). The mixture was dissolved in anhydrous acetone, potassium carbonate was added, and the reaction was carried out at room temperature for 8 hours. After the reaction was completed by TLC monitoring, the acetone was dried and separated by silica gel column chromatography (petroleum ether: acetone = 30: 1) to obtain the target product 9 (315 mg, yield 55.6%).
[0169] NMR data: 13 C NMR (125MHz, CDCl3)δ C 207.6(s),167.3(s),150.7(s),150.5(s),139.7(s),138.8(s),132.3(d),128.1(d),127.8(d),124.8(d),121.6(d),116.1(d),111.6( s),94.6(s),75.7(t),62.1(s),52.9(s),52.6(d),51.7(q),49.0(t),43.5(t),42.2(t),40.0(s),31.7(t),30.8(q),27.8(t),7.8(q).
[0170] Embodiment 14
[0171] [(1R,3aR,10bR,13S,3a 1 S)-3a-ethyl-9-iodo-1-(2-oxypropylidenepropyl)-6-{[(2,2,2-trichloroethyl)oxy]carbonyl}-3a,3a 1 ,4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylic acid methyl ester] compound 10a) has the following structural formula and synthesis steps:
[0172]
[0173] The compound tabersonine in Example 1 was replaced by compound 9 in Example 13, and the other steps and operations were the same as in Example 1.
[0174] NMR data: 13 C NMR (125MHz, CDCl3)δ C 207.4(s),167.1(s),150.4(s),149.6(s),141.4(s),139.6(s),136.8(d),131.9(d),130.6(d),127.9(d),118.0(d),111.8(s),94.5( s),88.1(s),75.8(t),62.6(d),53.0(s),52.4(d),51.8(q),49.5(t),43.9(t),42.1(t),39.3(s),32.0(t),31.0(q),28.2(t),7.8(q).
[0175] Embodiment 15
[0176] (1R,3aR,10bR,13S,3a 1 S)-9-bromo-3a-ethyl-1-(2-oxypropylidene)-6-{[(2,2,2-trichloroethyl)oxy]carbonyl}-3a,3a 1 The structural formula and synthesis steps of methyl 4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate (Compound 10b) are as follows:
[0177]
[0178] The compound tabersonine in Example 2 was replaced by compound 9 in Example 13, and the other steps and operations were the same as in Example 2.
[0179] NMR data: 13 C NMR (125MHz, CDCl3)δ C207.3(s),171.7(s),150.2(s),146.2(s),138.1(s),134.2(s),133.8(d),131.1(d),128.2(d),121.4(d),117.3(s),93.5(s),82.1(s) ),76.0(t),62.5(d),54.5(s),51.9(d),51.8(q),50.6(t),46.3(t),46.2(t),36.3(s),35.9(t),30.2(q),27.8(t),23.2(t),8.6(q).
[0180] Example 16
[0181] [(1R,3aR,10bR,13S,3a 1 S)-3a-ethyl-9-nitro-1-(2-oxypropylidene)-6-{[(2,2,2-trichloroethyl)oxy]carbonyl}-3a,3a 1 The structural formula and synthesis steps of methyl 4,6,11,12-hexahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate] (Compound 10c) are as follows:
[0182]
[0183] The compound 6 in Example 11 was replaced by the compound 9 in Example 13, and the other steps and operations were the same as those in Example 11.
[0184] NMR data: 13 C NMR (125MHz, CDCl3)δ C 207.4(s),167.2(s),150.9(s),145.8(s),145.6(s),141.2(d),131.9(s),129.7(d),125.5(d),118.5(d),116.1(d),113.4(s),95.4( s),89.1(s),76.5(t),62.7(d),53.2(s),52.1(d),49.5(t),43.5(t),42.0(t),40.6(s),28.3(t),27.5(q),23.2(t),22.8(t),7.7(q).
[0185] Test Example 1
[0186] The antiproliferative activity of glycyrrhizin and the compounds prepared in the examples were evaluated in the tumor cell line antiproliferative activity test:
[0187] (1) Experimental principle
[0188] MTT is the full name of 3-(4,5-dimethy1-2-thiazolyl)-2,5-diphenyl-2-H-tetrazoliumbromide, Thiazolyl Blue Tetrazolium Bromide, and its Chinese name is 3-(4,5-dimethylthiazole-2)-2,5-diphenyl tetrazolium bromide, which is a yellow dye. The detection principle is that the succinate dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystalline formazan and deposit it in the cells, while dead cells do not have this function. Dimethyl sulfoxide (DMSO) can dissolve the formazan in the cells, and its light absorption value is measured at a wavelength of 490nm using an enzyme marker. Within a certain range of cell numbers, the amount of MTT crystals formed is proportional to the number of living cells. The proportion of living cells is judged based on the measured absorbance value (OD). The larger the OD value, the greater the proportion of living cells and the smaller the cytotoxicity. On the contrary, the smaller the OD value, the stronger the cytotoxicity.
[0189] (2) Experimental subjects
[0190] A549 (lung cancer cells), MDA-MB-231 (breast cancer cells), KB (human oral epidermoid carcinoma cells), KB-VIN (nasopharyngeal carcinoma resistant cells), MCF-7 (breast cancer cells);
[0191] Test samples: some of the synthesized compounds;
[0192] Positive control: vinblastine (PXL).
[0193] (3) Experimental methods
[0194] Cytotoxic activity was determined using five human tumor cell lines, including A549 (lung cancer cells), MDA-MB-231 (breast cancer cells), KB (human oral epidermoid carcinoma cells), KB-VIN (nasopharyngeal carcinoma drug-resistant cells), and MCF-7 (breast cancer cells). The cell culture medium was RPMI-1640 or DMEM medium (Hyclone, USA) supplemented with 10% fetal bovine serum (Hyclone, USA), and the culture conditions were 37°C and 5% CO2. The cytotoxic activity of the compounds was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliu m bromide) method in a 96-well plate. 5000 cells were inoculated in each well of a 96-well plate and incubated in a 37°C, 5% CO2 incubator. After the cells adhered, paclitaxel (PXL, Sigma, USA) was used as a positive control, and the test compounds dissolved in DMSO (at concentrations of 1.25, 2.5, 5, 10, 20, and 40 μM) were used to treat the cell lines for 48 hours. The cell viability was then measured: 10 μL of MTT solution (5 mg / mL) was added to each well and incubated in a 37°C, 5% CO2 incubator for 4 hours. The supernatant was removed, 100 μL of DMSO was added to the 96-well plate, and the absorbance was tested at 490 nm using a microplate reader after shaking for 10 minutes. Compared with the control group DMSO, the drug concentration at which the cell proliferation inhibition rate was 50% (IC 50 ) are the average values (three independent repeated experiments).
[0195] (4) Experimental results
[0196] Table 1 Tumor cell line proliferation inhibitory activity (IC 50 ,Average±SD(μM))
[0197]
[0198]
[0199] Note: The sample numbers in Table 1 are the compound numbers in the examples, and 1 is glycyrrhizin.
[0200] From the data in Table 1, it can be seen that most of the compounds showed μM-level inhibitory activity on the five tumor cell lines, among which compound 9 in Example 13 had inhibitory activities of 4.843, 4.949, 4.602, 4.988, and 5.009 μM on cell lines A549, MDA-MB-231, KB, KB-VIN, and MCF-7, respectively. It can be seen that this type of compound has potential significance in the clinical treatment of the above tumors.
[0201] Test Example 2
[0202] The PI3Kα inhibitory activity test was performed on compound 9 in Example 13 having significant anti-tumor activity:
[0203] PI3-Kinase Activity ELISA: Pico kit (K-1000s) is used to screen PI3Kα kinase inhibitors. The kit quantifies the reaction product PIP3 by competitive ELISA to reflect the kinase activity of PI3Kα in the test sample. Purified PI3K class I lipid kinases, including p110α / p85α (Promega, Madison, WI, USA), were incubated with the compounds in Example 13 at room temperature for 30 min. PI3K activity was assessed using the PI3K Kinase Activity ELISA kit according to the product description. This method is a competitive ELISA detection method, and its signal is inversely proportional to the amount of PI(3,4,5)P3 produced. After the reaction is completed, PI3-Kinase first mixes the reaction product with the protein detected by PI(3,4,5)P3 and then adds it to the PI(3,4,5)P3 coated microplate for competitive binding. The colorimetric signal is inversely proportional to the amount of PI(3,4,5)P3 produced by PI3-Kinase. The absorbance at 450 nm was measured using a multifunctional microplate reader (PerkinElmer, Waltham, MA, USA).
[0204] The results of the PI3Kα inhibitory activity of the compound in Example 13 are as follows Figure 1 As shown, its IC 50 It is 8.08μM.
[0205] Test Example 3
[0206] In vivo anti-tumor efficacy and toxicity study of the inhibitor of Example 13:
[0207] The test animals were male MDA-MB-231 xenograft mice, 6 in each group. The drug was compound 9 in Example 13, and the drug dosage was set as shown in Table 2:
[0208] Table 2 Drug dosage configuration
[0209]
[0210]
[0211] Experimental methods:
[0212] The MDA-MB-231 nude mouse in vivo transplanted tumor model was established, and a blank group, a model group, and a drug administration group were set. When the tumor grew to a suitable state, 18 tumor-bearing nude mice with good growth status and uniform tumor size were selected and randomly divided into 3 groups, 6 in each group, namely the model group (DMSO group), the low-dose group of Example 13 (6 mg / kg), and the high-dose group of Example 13 (12 mg / kg). The low-dose and high-dose groups of the test drug Example 13 were administered by intraperitoneal injection, once every 2 days for 20 consecutive days, and the model group was given an equal volume of solvent control. The anti-tumor effect of the test substance was dynamically observed using the method of measuring tumor diameter. The body weight and tumor volume of nude mice were measured every 3 days. The mice were killed on the 20th day, and the tumor mass was surgically removed to measure its volume and weight.
[0213] Figure 2 The results of the in vivo anti-tumor efficacy and toxicity study of the compound in Example 13, wherein (A) is the growth curve of nude mouse body weight; (B) is the change curve of mouse tumor volume; (C) is a representative image of mouse tumor tissue; (D) is the average tumor weight of mice at the end of the experiment. The experimental results show that: under the treatment of the test drug Example 13 at a low dose of 6 mg / kg and a high dose of 12 mg / kg, the volume of mice did not decrease significantly, indicating that the test drug had no obvious cytotoxicity. Compared with the model group, the relative size of the tumor was 74.03% and 28.03% of the model group, indicating that tumor growth can be effectively inhibited at low and high concentrations. The test drug prepared in Example 13 has a significant inhibitory effect on the growth of nude mouse xenograft tumors of human breast cancer MDA-MB-231.
[0214] The present invention evaluates the proliferation inhibitory activity of glycyrrhizin PI3Kα inhibitors on 5 tumor cell lines and tests the PI3Kα inhibitory activity, and evaluates its anti-tumor efficacy based on the MDA-MB-231 xenograft tumor model, indicating that glycyrrhizin compounds have great potential in the clinical treatment of breast cancer and can be used as lead molecules for the development of anti-tumor drugs.
[0215] Although the above-mentioned embodiments have made a detailed description of the present invention, they are only some embodiments of the present invention, rather than all embodiments. People can also obtain other embodiments based on the embodiments of the present invention without creative work, and these embodiments all fall within the scope of protection of the present invention.
Claims
1. A PI3Kα inhibitor, characterized in that The PI3Kα inhibitor is a glycyrrhizin compound, and its stereoisomers or pharmaceutically acceptable salts. The structural formula of the glycyrrhizin compound is shown in Formula I or Formula II: In formula I and formula II, R1 is selected from hydrogen, halogen, methoxy, nitro, cyano, trimethylsilylethynyl or phenyl; R2 is selected from hydrogen or acetonyl; A is selected from hydrogen, tert-butyloxycarbonyl or trichloroethoxycarbonyl; In the formula I, R1, R2 and A are not hydrogen at the same time.
2. The PI3Kα inhibitor according to claim 1, characterized in that The structural formula of the glycyrrhizin compound is Formula I, wherein A is hydrogen, R1 is iodine, bromine, nitro, cyano, trimethylsilylethynyl or phenyl, and R2 is hydrogen.
3. The PI3Kα inhibitor according to claim 1, characterized in that The structural formula of the glycyrrhizin compound is Formula I, wherein A is tert-butyloxycarbonyl, R1 is hydrogen, iodine or methoxy, and R2 is hydrogen.
4. The PI3Kα inhibitor according to claim 1, characterized in that The structural formula of the glycyrrhizin compound is Formula I, wherein A is trichloroethoxycarbonyl, R1 is hydrogen, iodine, bromine or nitro, and R2 is hydrogen or acetone.
5. The PI3Kα inhibitor according to claim 1, characterized in that The structural formula of the glycyrrhizin compound is formula II, wherein A is trichloroethoxycarbonyl, R1 is hydrogen, and R2 is hydrogen.
6. The PI3Kα inhibitor according to claim 1, characterized in that The glycyrrhizin compound is one of the following structures:
7. The method for preparing the PI3Kα inhibitor according to any one of claims 1 to 6, characterized in that: The following steps are involved: Using glycyrrhizin as a raw material, structural modification and / or oxidation of the N-4 position are performed to obtain a PI3Kα inhibitor; the positions of the structural modification include at least one of the N-1 position, the C-3 position and the C-10 position; the modification group at the C-10 position is selected from hydrogen, halogen, methoxy, nitro, cyano, trimethylsilylethynyl or phenyl; the modification group at the C-3 position is selected from hydrogen or acetonyl; the modification group at the N-1 position is selected from hydrogen, tert-butyloxycarbonyl or trichloroethoxycarbonyl.
8. The preparation method according to claim 7, characterized in that: If the structural formula of the hydrolicycitriol compound is Formula I, the modifying group at the N-1 position is trichloroethoxycarbonyl, the modifying group at the C-10 position is hydrogen, and the modifying group at the C-3 position is acetone, the preparation method comprises the following steps: After glycyrrhizin is protected by 2,2,2-trichloroethoxycarbonyl, an oxidation reaction is performed, and then a nucleophilic addition reaction is performed to obtain a PI3Kα inhibitor.
9. The preparation method according to claim 7, characterized in that: If the structural formula of the hydrolicycitriol compound is Formula I, the modifying group at the N-1 position is trichloroethoxycarbonyl, the modifying group at the C-10 position is halogen or nitro, and the modifying group at the C-3 position is acetone, the preparation method comprises the following steps: After glycyrrhizin is protected by 2,2,2-trichloroethoxycarbonyl, an oxidation reaction is performed, a nucleophilic addition reaction is performed, and then an aromatic ring substitution reaction or a nitration reaction is performed to obtain a PI3Kα inhibitor.
10. Use of the PI3Kα inhibitor according to any one of claims 1 to 6 or the PI3Kα inhibitor obtained by the preparation method according to any one of claims 7 to 9 in the preparation of a drug for preventing and / or inhibiting tumor growth.
